While CTCs have still not been validated for use in clinical settings for disease management for patients with NSCLC, ctDNA was approved by the U.S. Food and Drug Administration (FDA) in 2016 as the first liquid biopsy test for patients with NSCLC in which ctDNA is analyzed for the presence of specific mutations to identify patients eligible for treatment with EGFR-targeted therapy [8]. Here, EGFR is linked to non-small cell lung carcinoma.